Drug Discovery for Parkinson's With Mutations in the GBA Gene

Study Overview
=================
Brief Summary
-----------------
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.

Detailed Description
-----------------
Researchers at the New York Stem Cell Foundation (NYSCF) Research Institute study diverse diseases, conditions, and traits by creating stem cells from biological samples. These pluripotent stem cells can become any cell in the human body, including cells that may be difficult, invasive, or impossible to obtain directly. Additionally, researchers perform genetic testing to learn more about DNA, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). A piece of DNA that determines the specific role of a cell is called a gene. If the instructions in a gene are abnormal, this can lead to disease. Participation in the study involves: (1) completion of health questionnaires, (2) providing a skin and/or blood sample from which stem cells may be created, (3) collection of a saliva sample for genetic analysis, and (4) possible future follow-up to provide additional information or learn about other research studies. This study is not a clinical trial.

Official Title
-----------------
Drug Discovery for Parkinson's With Mutations in the GBA Gene

Conditions
-----------------
Parkinson Disease, Gaucher Disease, Healthy, GBA Gene Mutation

Intervention / Treatment
-----------------
* Other: Biological Sample Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older. Diagnosis of Parkinson's disease, Gaucher disease, or healthy control. Must provide written informed consent unless physical limitations preclude signing. Exclusion Criteria: For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection. For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection. For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Parkinson's Disease<br>Subjects in this group will have a diagnosis of Parkinson's disease with or without a known GBA gene mutation. | Other: Biological Sample Collection<br>* Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)<br>* Other names: Biological sample collection for biobanking and research;|
| Gaucher Disease<br>Subjects in this group with have a diagnosis of Gaucher disease with or without a known GBA gene mutation. | Other: Biological Sample Collection<br>* Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)<br>* Other names: Biological sample collection for biobanking and research;|
| Healthy Control<br>Subjects in this group will serve as healthy controls. | Other: Biological Sample Collection<br>* Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)<br>* Other names: Biological sample collection for biobanking and research;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information. | Establish a robust disease signature using a cohort of PD and carefully matched control samples to screen a library of approximately 3,000 compounds to determine whether any compounds improve or reverse disease phenotypes. | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson Disease, GBA Gene Mutation